Trials / Unknown
UnknownNCT04586088
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
Apatinib Combined With Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Failed at Least the First-line Treatment
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
Conditions
- Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Chemotherapy Effect
- Immunotherapy
- Molecular Targeted Therapy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib plus Camrelizumab | Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision. |
Timeline
- Start date
- 2020-05-05
- Primary completion
- 2022-06-02
- Completion
- 2023-09-05
- First posted
- 2020-10-14
- Last updated
- 2023-05-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04586088. Inclusion in this directory is not an endorsement.